- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
Brazil Vitamin K2 Market is expected to reach US$ 9.81 million by 2028
Jun 09, 2023
Europe pharmaceutical drug delivery market is expected to reach US$ 562,102.6 Mn by 2027
Oct 06, 2020
Novartis scraps sale of assets including COVID-19 hopeful to Indis's Aurobindo Pharma
Apr 02, 2020
Asia Pacific Starch Softgel Capsules Market Size, Share, Demand, Analysis and Forecast To 2027 | Hunan Er-Kang Pharmaceutical Co. Ltd,Softcaps,Fuji Capsule Co. Ltd.,Aenova Holding GmbH,Sirio Pharma Co. Ltd.
Oct 15, 2020
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
Jun 20, 2020
Tiamulin Market Trends, Strong Application Scope, Key Players, Growth Overview and Forecast by 2027
Mar 23, 2021
Radiopharmaceutical Theragnostics Market is expected to reach US$ 3,441.97 million by 2028
Mar 27, 2023
Follow us on
